Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
B-Cell Lymphoma
Research from Y.H. Park and co-researchers in the area of B-cell lymphoma published
May 12th, 2009
According to a study from Seoul, South Korea, "Rituximab may overcome bcl-2-mediated chemoresistance through the inhibition of interleukin-10 (IL-10)-mediated loops, thus down-regulating bcl-2 expression. We examined the effects of genetic variation in BCL2/IL10 gene loops on treatment outcomes of diffuse large B-cell lymphoma when treated with either CHOP or rituximab plus CHOP (R-CHOP) chemotherapy." "Four genotypes were tested including BCL2 -938 C> A (rs2279115), +21 A> G (rs1801018), IL10 -819 T> C (rs1800871), and -592 A> C (rs1800872) in patients receiving either R-CHOP (n = 125) or CHOP (n = 110). IL10 SNPs, -819 TT/TC or -592 AA/AC genotypes...
Source: Cancer Weekly (2009-05-12)
|
